Effect of anti-inflammatory activity of ranolazine in rat model of inflammation

Naveena, R; Hashilkar, Nayana K.; Davangeri, Reshma; Majagi, Suneel Ishwar

doi:10.4103/ijmr.ijmr_1504_16

Cited by 7 publications

(2 citation statements)

References 15 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Suppression of these pathways and prevention of ROS formation are essential for reducing the severity of MTX-related organ damage (Jaeschke et al, 2002;Song et al, 2006). Recent studies have investigated the mechanism of action of ranitidine (RAN) in this regard (Naveena et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

A potential hepatoprotective effect of ranolazine against methotrexate-induced liver injury in rats

Polat

Sarı

Tanriverdi

et al. 2023

Preprint

View full text Add to dashboard Cite

Methotrexate (MTX) is an important drug for rheumatic and non-rheumatic disease therapy. MTX has been associated with many adverse effects ranging from asymptomatic transaminase elevation to fibrotic tissue formation and fatal hepatic necrosis due to oxidative stress. Concerns regarding potential liver toxicity have led to the avoidance of medication, termination, or advice for inquiries in clinical care. The protective and therapeutic effects of a new generation anti-angina drug, ranolazine (RAN), on MTX-induced liver damage were investigated by evaluating its antioxidant mechanism in rats. Thirty-two female Wistar Albino rats were randomly assigned to Control, RAN, prophylaxis, and treatment groups (n=8/group). Liver function enzymes, histopathological assessment and serum biochemical parameters were examined. Malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT), and reduced glutathione (GSH) were also measured in liver tissue. MTX administration caused mononuclear inflammation, vascular congestion, ductal proliferation, vacuolization, and fibrosis as evaluated using Roening grading and increases in aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, and lactate dehydrogenase levels ( p<0.05) in the blood, which is compatible with hepatocyte damage in the blood and increased MDA levels in the tissue. Histopathologically, vascular congestion and ductal proliferation, and biochemically, MDA and SOD levels and serum biochemical parameters, significantly decreased in the RAN+MTX and MTX+RAN groups ( p<0.001) when compared with the MTX group. No significant changes were observed in terms of SOD and GSH levels and fibrosis scores in RAN-administered groups ( p>0.05). According to our results, RAN may be a potential hepatoprotective agent against MTX-induced liver injury.

show abstract

Section: Discussionmentioning

confidence: 99%

A potential hepatoprotective effect of ranolazine against methotrexate-induced liver injury in rats

Polat

Sarı

Tanriverdi

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…While there are studies in the literature on the effect of ranolazine on blood glucose, its anti-inflammatory effect and its antioxidant effect, apart from its cardiac effects, there is no study on its effect on flap viability (11)(12)(13)(14). This study aimed to investigate the effects of ranolazine on the viability of modified Mcfarlane skin flaps with random circulation pattern prepared on rats.…”

Section: Introductionmentioning

confidence: 99%

The effect of Ranolazine on random pattern skin flap survival in rats

Öztürk¹,

Koçer²,

Koca³

et al. 2023

Med Sci Discov

View full text Add to dashboard Cite

Objective: Flap surgery is widely used in the field of plastic surgery for defect reconstruction. The most important problem of this surgery is ischemic necrosis which may occur in the distal of the flap. For this reason, studies have been conducted to develop many treatment methods to solve this problem. Our study aimed to investigate the effects of different doses of ranolazine, a selective late sodium current blocker, on the viability of skin flaps prepared from the back of the rat. Material and Methods: A total of 32 rats, including 8 rats in each group, were included in the study. A random patterned caudal base 3x9 cm width : length modified McFarlane skin flap was elevated from the backs of all rats and adapted back to its place For 7 days postoperatively, 1 cc of saline was added to the control group (Group A), and 45 mg/kg, 90 mg/kg, and 180 mg/kg of ranolazine were added to the study groups (Group B, C, D), respectively, and administered daily with gastric lavage On the 7th postoperative day, photographs were taken to evaluate the viability of the flaps and scintigraphic evaluations were made. After the rats were sacrificed, the flaps were separated from their bases and evaluated histopathologically. Results: As a result of the evaluations, the viable flap area was calculated as 12.7548 cm2 for Group A, 14.9533 cm2, 16.494 cm2 and 16.7599 cm2 for Groups B, C and D, respectively, and a statistically significant difference was found between the groups (P = 0.00 <0.05 ). The viable flap area percentages were calculated as 57.486% for Group A, 68.908% for Group B, 70.174% for Group C and 74.603% for Group D, and a statistically significant difference was found between the groups (P = 0.00 <0.05). As a result of scintigraphic evaluation, the viable flap area was found to be 61.57% for Group A, 71.04% for Group B, 70.21% for Group C and 73.85% for Group D, and a statistically significant difference was found between the groups (P = 0.03 <0.05). Histopathological evaluation revealed a decrease in the flaps' inflammation, edema and necrosis scores with the increasing drug dose. Conclusion: As a result, although flap viability increased with increasing doses in the group given ranolazine, more detailed studies are needed before it can be used clinically.

show abstract